Sugi Predict

Sugi Predict / Compounds / SCHEMBL2934064

SCHEMBL2934064

SCHEMBL2934064

O=C(Oc1ccccc1)c1cnccc1CN1CC(=O)N(c2ccc(SC(F)(F)F)cc2)C1=O

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 9/20 0.37
▸ ENPP2 Q13822 2/20 0.36
▸ PPARD Q03181 2/20 0.36
▸ PPARA Q07869 2/20 0.36
▸ KMT2A Q03164 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TAS2R8 Q9NYW2 2/20 0.33
▸ KDM5A P29375 1/20 0.33
▸ KDM4C Q9H3R0 1/20 0.33
▸ KDM5B Q9UGL1 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940413 0.89 PPARD (0.39) ENPP2PPARDPPARAKMT2APOLB
SCHEMBL2939581 0.88 IGF1R (0.42) IGF1RENPP2PPARDPPARATAS2R8
SCHEMBL2937867 0.86 IGF1R (0.40) IGF1RPPARDPPARATAS2R8PPARG
SCHEMBL3732826 0.86 IGF1R (0.41) IGF1RENPP2PPARDPPARATAS2R8
SCHEMBL2941567 0.86 IGF1R (0.36) IGF1RENPP2PPARDPPARASMN1; SMN2
SCHEMBL2939214 0.86 IGF1R (0.38) IGF1RENPP2PPARDPPARAKMT2A
SCHEMBL2932764 0.85 IGF1R (0.42) IGF1RENPP2PPARDPPARATAS2R8
SCHEMBL2938979 0.85 ENPP2 (0.38) IGF1RENPP2PPARDPPARAKMT2A
SCHEMBL2942229 0.85 NPC1 (0.40) IGF1RENPP2PPARDPPARASMN1; SMN2
SCHEMBL2938965 0.84 IGF1R (0.39) IGF1RENPP2PPARDPPARATAS2R8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885ENPP2 3905/4885PPARD 3189/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885ENPP2 3920/4885PPARD 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.